Just In
- 1 hr ago These Common Habits Can Be Insidious, Can Hurt Any Partner And Ruin Any Relationship
- 4 hrs ago What Is Porcelain Doll Makeup Trend? 6 Tips To Achieve The Doll-like Glamour
- 6 hrs ago These Zodiac Signs Are Extremely Stubborn And Struggle When It Comes To Apologizing
- 8 hrs ago Daily Horoscope, 18 April 2024: Libra Will See Financial Success, Relationship With Spouse Will Improve
Don't Miss
- Travel Experience The Best Of Sydney At Vibrant Darling Harbour
- Finance Indian Railway Finance Corp IRFC: BUY Top Dividend Railway PSU Stock For 55% Gains Ahead; Target Rs 220
- Movies Article 370 OTT Release Date, Time & Platform: Yami Gautam Starrer Can Be Watched This Week! Know When & Where
- Sports Rohit Sharma says MS Dhoni is 'sick and tired' but easy to convince Dinesh Karthik for T20 World Cup 2024
- Automobiles Google Maps To Ease EV Charger Finding With Latest Updates
- News Rahul Gandhi Lacks The Bravery To Run In Amethi Polls, Claims Rajnath Singh
- Technology OnePlus 11R 5G Solar Red Edition Now Available With New Storage Configuration; Get It for Rs 34,999
- Education IIT Madras Introduces International master's course on Water Security and Global Change
Johnson & Johnson Gets Nod For Emergency Use: Everything You Need To Know About This Single-Dose Vaccine
What You Need To Know About J&J Covid-19 Vaccine
Credit: Reuters
As part of expanding its vaccine basket, India has given Emergency Use Authorisation (EUA) to the single-dose vaccine developed by Janssen Pharmaceuticals, a Belgium based subsidiary of the global major Johnson & Johnson.
Johnson & Johnson is the fifth vaccine to get approval for emergency use, after Covishield by AstraZeneca, Covaxin by Bharat Biotech Sputnik V by Russia's Gamaleya Institute and Moderna by Moderna Inc.
The US drugmaker Johnson & Johnson applied for Emergency Use Authorisation of their COVID-19 vaccine in India on August 5. The company claims the vaccine has proved to be 85 per cent effective in the clinical trials; the vaccine has also demonstrated resistance against Delta and other emerging variants. Hyderabad-based vaccine maker Biological E Ltd will produce the vaccine in the country.
Johnson & Johnson vaccine was issued an emergency use authorisation in the United States by the Food and Drug Administration on February 27, 2021. The European Union authorized the vaccine for emergency use as well.
"Johnson and Johnson's single-dose Covid-19 vaccine is given approval for Emergency Use in India. Now India has 5 EUA vaccines. This will further boost our nation's collective fight against COVID-19," Union Health Minister Mansukh Mandaviya tweeted on Sunday, 8 August 2021 [1].
"We are pleased to announce that on August 7, 2021, the Government of India issued Emergency Use Authorisation (EUA) for the Johnson & Johnson Covid-19 single-dose vaccine in India, to prevent Covid-19 in individuals 18 years of age and older," Johnson & Johnson's India spokesperson said in a statement as quoted by news agency ANI [2].
How Johnson & Johnson vaccine works
The single-dose vaccine, known as JNJ-78436735 or Ad26.COV2.S. was developed by Janssen Pharmaceutica, a Belgium-based division of Johnson & Johnson, in collaboration with Beth Israel Deaconess Medical Center.
Unlike Moderna and Pfizer which use mRNA technology-messenger RNA is a code that instructs the immune system to recognise and attack the COVID-19 virus- Johnson and Johnson's viral vector vaccine uses a disabled adenovirus.
The adenovirus is not linked to coronavirus and is a different virus altogether; however, it can carry the genetic messages into human cells and deliver instructions to the cells on how to recognise and defeat the coronavirus. The adenovirus in the vaccine will not replicate in the human body and cause a viral infection.
A single dose of the Johnson & Johnson vaccine is sufficient to immunise a person while other COVID-19 vaccines offer a two-shot immunisation. The vaccine can be kept under refrigerator temperature for months which makes it convenient for transportation and storage in remote and rural areas where it's challenging to bring mRNA vaccines that require freezing temperature. The vaccine is estimated to remain stable for two years at -20°C, and a maximum of 4.5 months at routine refrigeration temperatures of 2° to 8°C, according to the manufacturer [3].
Credit: Freepik
Efficacy of Johnson & Johnson Vaccine
Janssen Ad26.CoV2.S was found to have an efficacy of 85.4 per cent against severe disease and 93.1 per cent against hospitalisation 28 days after vaccination. In clinical trials a single dose of Janssen Ad26.COV2.S was found to have an efficacy of 66.9 per cent against moderate and severe SARS-CoV-2 infection.
Johnson & Johnson's COVID-19 vaccine showed a 72 per cent efficacy rate in a study conducted in the United States. While in South Africa it was found to be 64 per cent. Against severe forms of Covid-19, the vaccine showed 86 per cent efficacy in the US and 82 per cent in South Africa [4].
As per a study published in The New England Journal of Medicine, Johnson & Johnson's vaccine showed an overall efficacy of 66.3 per cent in mild to moderate COVID-19 cases, and an overall 76.3 per cent efficacy in the cases of Severe to critical COVID-19 [5].
Side effects of Johnson & Johnson vaccine
The WHO Strategic Advisory Group of Experts (SAGE) on Immunisation after thoroughly assessing the data on quality, safety and efficacy of the vaccine recommended its use for "people aged 18 and above [6]."
The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) also reviewed Johnson & Johnson's vaccine and found it to be safe for use.
The vaccine may have some typical side effects associated with all the COCID-19 vaccines: redness, swelling, and pain at the injection site, fever, fatigue, headache, chills, nausea, vomiting, diarrhoea, muscle pain, and/or joint pain [7].
On
April
13,
2021,
the
FDA
and
CDC
called
for
a
pause
in
the
use
of
the
Johnson
&
Johnson
COVID-19
vaccine
following
a
report
of
a
"rare
and
severe" blood
clot
in
six
participants.
However,
the
pause
was
lifted
a
week
later
after
following
a
safety
review
[8].
European Medicines Agency (EMA) added Guillain-Barré syndrome, a rare nerve-degeneration disorder, as a possible rare side effect of Johnson & Johnson's Covid-19 vaccine [9].
Is Johnson & Johnson vaccine effective against the Delta variant?
According to an article published on Johnson & Johnson's official website, their single-shot COVID-19 vaccine generated "strong, persistent activity" against the Delta variant [10].
According to a trial, called Sisonke, the single-dose shot showed a 71 per cent efficacy against hospitalisation and as much as 96 per cent efficacy against death [11].
- wellnessGap Between Second And Precaution Dose Of Covid-19 Vaccine Reduced To 6 Months
- wellnessNovel Inhalable Covid-19 Vaccine Is Stable At Room Temperature: Study
- wellnessNTAGI To Review Covaxin Corbevax Data For 6-12 Years Thursday, Discuss Reducing Booster Dose Gap
- wellnessEven Vaccinated People Can Develop Long Covid, Study Finds
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study
- basicsNovavax's Covid-19 Vaccine Covovax Gets Emergency Use Authorisation For 12-17 Age Group In India
- wellnessAIIMS Delhi To Start Booster Dose Trial Of Intranasal Covid Vaccine From March 11
- wellnessDecision On COVID-19 Vaccine Precaution Dose For All Adults Will Be Based On Scientific Need: Govt
- healthIsrael To Administer Fourth Dose Of COVID-19 Vaccine For Medical Personnel And Senior Citizens
- healthHospital Launches Vaccination Programme For Children Aged 15-18 Yrs Across The Country
- healthSII Gets DCGI Nod To Manufacture Drug Substance, Test It For Developing Jab Against Omicron
- healthDecision On Which Vaccine To Be Given As Precautionary Dose Expected Soon: Govt